Tumor Metabolism of Lung Cancer in Patients Who Underwent Percutaneous Radiation Measured With F-18-FDG-PET
Completed
- Conditions
- Lung Cancer
- Registration Number
- NCT00180154
- Lead Sponsor
- Technische Universität Dresden
- Brief Summary
The purpose of the study is to describe the regional and global FDG-kinetics in non-small-cell lung cancer (NSCLC) during percutaneous radiation therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Histologically confirmed NSCLC not curable by surgery
- Karnofsky > 80%
- Tumor volume and localization allow curative radiotherapy
- Written consent
Exclusion Criteria
- Metastases
- Diabetes
- Pregnancy
- Psychiatric impairment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie FDG-kinetics changes in NSCLC during percutaneous radiation therapy?
How does percutaneous radiation therapy impact tumor metabolism compared to standard external beam radiotherapy in NSCLC?
Which biomarkers correlate with metabolic response to percutaneous radiation in NCT00180154 lung cancer patients?
What adverse events are associated with FDG-PET monitoring during percutaneous lung cancer radiation therapy?
Are there combination therapies with percutaneous radiation that enhance metabolic response in NSCLC measured by FDG-PET?
Trial Locations
- Locations (1)
Department of Nuclear Medicine
🇩🇪Dresden, Germany
Department of Nuclear Medicine🇩🇪Dresden, Germany